Hester Biosciences spurts on collaborating with IIT Guwahati for COVID-19 vaccine

Image
Capital Market
Last Updated : Apr 29 2020 | 3:51 PM IST

Hester Biosciences hit an upper circuit limit of 20% at Rs 1,366.90 after the company said it collaborated with IIT Guwahati to develop vaccine against COVID-19.

Hester Biosciences announced that it is collaborating with Indian Institute of Technology (IIT) Guwahati to work on the vaccine development against COVID-19. The agreement between the two parties was signed on 15 April 2020.

The vaccine will be based on recombinant avian paramyxovirus based vector platform. The avion paramyxovirus-1 has been explored as a vaccine vector for various animals and human pathogens. The avion paramyxovirus-1 has been used to express the immunogenic protein of human pathogens such as HIV, avion influenza virus, human parainfluenza virus, SARS-CoV. Similarly, it has also been explored as a vaccine vector for animal pathogens such as infectious bursal disease virus, infectious laryngotracheitis virus, bovine herpes virus, Nipah virus etc.

IIT Guwahati and Hester Biosciences expect the vaccine to be ready by the end of this year to start animal studies. The work is currently in its early stage of development.

Commenting on the vaccine development, Dr. Sachin Kumar, the associate professor of Department of Biosciences and Bioengineering in IIT Guwahati, says that, "It is too early to comment on the efficacy and immunogenicity of the vaccine, however, we will be able to reveal more details about this vaccine after the results of animal studies are obtained."

Meanwhile, the company said that Chetas Patel will replace Sahil Shah as a chief financial officer (KMP) of the company with effect from 29 April 2020.

Hester Biosciences' consolidated net profit dropped 10% to Rs 11.52 crore on a 10.8% jump in net sales to Rs 50.69 crore in Q3 December 2019 over Q3 December 2018.

Hester Biosciences is engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include poultry division and large animal division.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 29 2020 | 3:04 PM IST

Next Story